Pfizer Upbeat About Study Results For NSCLC Treatment

Published: 30-May-2009

Pfizer has reported positive results from studies evaluating the anti-insulin growth factor type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), in patients with non-small cell lung cancer (NSCLC). Figitumumab, an investigational fully human monoclonal antibody, is a highly specific inhibitor of the insulin growth factor-1 receptor (IGF-1R) pathway.

During the clinical trial, 151 blood samples were analyzed from 42 patients enrolled in the randomized Phase II study of figitumumab in combination with carboplatin and paclitaxel in NSCLC patients. They observed elevated plasma levels of fIGF-1 in patients with adenocarcinoma compared with those with squamous cell carcinoma (P=0.0326) and with large cell carcinoma (P=0.026).

Dr. Mace Rothenberg, Senior Vice President of Clinical Development and Medical Affairs of Oncology Business Unit at Pfizer, said: “As we try to find the right drug to use in the right setting for each patient, we are encouraged by these data, suggesting a relationship between tumor histology and response to figitumumab. Given that patients with advanced NSCLC face a poor prognosis, it is important to be able to identify specific patients who may benefit most from different treatment options.”

Tell your friend about this article